

Washington University School of Medicine

Digital Commons@Becker

2020-Current year OA Pubs

Open Access Publications

8-22-2023

Genomic landscape of TP53-mutated myeloid malignancies

Haley J Abel

Karolyn A Oetjen

Christopher A Miller

Sai M Ramakrishnan

Ryan B Day

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/oa_4

 Part of the [Medicine and Health Sciences Commons](#)

Please let us know how this document benefits you.

Authors

Haley J Abel, Karolyn A Oetjen, Christopher A Miller, Sai M Ramakrishnan, Ryan B Day, Nichole M Helton, Catrina C Fronick, Robert S Fulton, Sharon E Heath, Stefan P Tarnawsky, Sridhar Nonavinkere Srivatsan, Eric J Duncavage, Molly C Schroeder, Jacqueline E Payton, David H Spencer, Matthew J Walter, Peter Westervelt, John F DiPersio, Timothy J Ley, and Daniel C Link

Genomic landscape of *TP53*-mutated myeloid malignancies

Haley J. Abel,^{1,*} Karolyn A. Oetjen,^{1,*} Christopher A. Miller,^{1,*} Sai M. Ramakrishnan,¹ Ryan B. Day,¹ Nichole M. Helton,¹ Catrina C. Fronick,² Robert S. Fulton,² Sharon E. Heath,¹ Stefan P. Tarnawsky,¹ Sridhar Nonavinkere Srivatsan,¹ Eric J. Duncavage,³ Molly C. Schroeder,³ Jacqueline E. Payton,³ David H. Spencer,^{1,3} Matthew J. Walter,¹ Peter Westervelt,¹ John F. DiPersio,¹ Timothy J. Ley,¹ and Daniel C. Link¹

¹Division of Oncology, Department of Medicine, ²McDonnell Genome Institute, and ³Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO

Key Points

- Telomere content is increased in *TP53*-mutated AML/MDS compared with other AMLs, implicating altered telomere maintenance for pathogenesis.
- Alterations of *ETV6* and *NF1* are frequent cooperating events in *TP53*-mutated AML/MDS.

TP53-mutated myeloid malignancies are associated with complex cytogenetics and extensive structural variants, which complicates detailed genomic analysis by conventional clinical techniques. We performed whole-genome sequencing (WGS) of 42 acute myeloid leukemia (AML)/myelodysplastic syndromes (MDS) cases with paired normal tissue to better characterize the genomic landscape of *TP53*-mutated AML/MDS. WGS accurately determines *TP53* allele status, a key prognostic factor, resulting in the reclassification of 12% of cases from monoallelic to multihit. Although aneuploidy and chromothripsis are shared with most *TP53*-mutated cancers, the specific chromosome abnormalities are distinct to each cancer type, suggesting a dependence on the tissue of origin. *ETV6* expression is reduced in nearly all cases of *TP53*-mutated AML/MDS, either through gene deletion or presumed epigenetic silencing. Within the AML cohort, mutations of *NF1* are highly enriched, with deletions of 1 copy of *NF1* present in 45% of cases and biallelic mutations in 17%. Telomere content is increased in *TP53*-mutated AMLs compared with other AML subtypes, and abnormal telomeric sequences were detected in the interstitial regions of chromosomes. These data highlight the unique features of *TP53*-mutated myeloid malignancies, including the high frequency of chromothripsis and structural variation, the frequent involvement of unique genes (including *NF1* and *ETV6*) as cooperating events, and evidence for altered telomere maintenance.

Introduction

Myeloid malignancies with complex cytogenetics have adverse prognostic risk,¹ and *TP53* mutations are present in ~70% of such cases.² Extensive structural variation makes it difficult to completely characterize their genomes using standard clinical techniques for diagnosis and risk stratification,^{1,3} such as karyotyping, fluorescence in situ hybridization (FISH), targeted sequencing panels, and immunohistochemistry. Multiple genomic alterations of the *TP53* locus indicate extremely poor prognosis in myelodysplastic syndromes (MDS).⁴ Although “multihit” *TP53* events may be detected by sequencing panels and cytogenetics, they are limited in resolution and generally rely on indirect evidence, such as high variant allele frequency (VAF) in sequencing panels (ie, exceeding 50%,^{1,3} 55%,⁵ or 60%⁶), and cannot deconvolute the effects of purity, ploidy, or clonality. Alternate approaches

Submitted 8 March 2023; accepted 7 June 2023; prepublished online on *Blood Advances* First Edition 20 June 2023; final version published online 11 August 2023.
<https://doi.org/10.1182/bloodadvances.2023010156>.

*H.J.A., K.A.O., and C.A.M. contributed equally to this study.
 Data sets are available in dbGaP under study phs000159.

The full-text version of this article contains a data supplement.

© 2023 by The American Society of Hematology. Licensed under [Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International \(CC BY-NC-ND 4.0\)](https://creativecommons.org/licenses/by-nc-nd/4.0/), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

include DNA microarray but small copy-number changes or complex structural events remain undetected with this method. Whole-genome sequencing (WGS) with adequate genome coverage can detect nearly all copy-number changes, structural variants (SV), single nucleotide variants (SNV), and small insertion/deletions (indels) in a tumor in an unbiased fashion, that is not limited to specific probes on FISH or sequencing panels.⁷

The pathogenesis of *TP53*-mutated acute myeloid leukemia (AML) and MDS is still unclear. We, and others, previously reported that *TP53* mutations are present years before the development of therapy-related *TP53*-mutated AML/MDS, suggesting that *TP53* mutations initiate events.⁸⁻¹⁰ Multiple previous studies have shown that *TP53* mutations are associated with aneuploidy and chromothripsis in both myeloid and other malignancies. Moreover, previous studies have shown that driver mutations commonly seen in other types of AML, such as mutations in *DNMT3A*, *NPM1*, and *FLT3*, are uncommon in *TP53*-mutated myeloid malignancies, suggesting that SV, including chromosome-level alterations, are providing the cooperating events needed for leukemic transformation.

To characterize the genomic landscape more thoroughly in *TP53*-mutated myeloid malignancies, we performed WGS on matched tumor/normal pairs from 42 patients. To our knowledge, these data provide the most detailed analysis to date of SV in *TP53*-mutated AML/MDS and yielded several new observations, including the identification of *NF1* and *ETV6* mutations as frequent cooperating events, and evidence for altered telomere maintenance.

Methods

Patient selection

All patients provided written informed consent for tissue repository and genomic sequencing in accordance with protocol #201011766 approved by the Washington University institutional review board. Cases were selected from patients with known pathogenic mutations or structural rearrangements in *TP53* with available material from both tumor and normal tissue. Bone marrow aspirates were used for tumor analysis when available, otherwise peripheral blood was used. Skin or buccal samples were used for matched normal specimens.

WGS and RNA sequencing

WGS was performed as previously described.⁷ Sequencing was performed on an Illumina NovaSeq S4 with 150–base pair paired end reads, targeting 60× coverage for tumors and 30× for matched normal samples. Sequencing depth and sample purity metrics for each case are summarized in supplemental Table 1. Estimated tumor purity of >20% (based on somatic VAFs) was required for inclusion.

Sequence data were aligned against reference sequence GRCh38 using BWA-MEM.¹¹ Aligned reads were sorted, deduplicated, and recalibrated by base quality score. SNVs and small indels were detected using MuTect2,¹² VarScan2,¹³ Strelka2,¹⁴ and GATK.¹⁵ SV were called using GRIDSS2.¹⁶ PURPLE was used for copy-number calling and detection of copy-neutral loss of heterozygosity (CN-LOH).¹⁷ LINX was used for clustering of SV into complex variants.¹⁸ Chromothripsis was assessed with ShatterSeek.¹⁹ Telomeric content was assessed with TelomereHunter.²⁰ Detection of telomeric insertions in intrachromosomal sequence was

performed, as previously described.²¹ Refer to supplemental Methods for full details of variant calling and telomere analysis.

RNA sequencing was performed as described in supplemental Methods.

Results

Clinical characteristics of patient cohorts

We performed WGS on 42 samples from patients with *TP53*-mutated AML or MDS. Cases were selected from patients with pathogenic mutations or structural rearrangements in *TP53* identified through panel sequencing, WGS, or cytogenetics at Washington University, including both previously published^{7,22,23} and newly identified cases. Paired normal tissue from each patient was used to ensure accurate distinction of somatic and germ line variants. Analysis was performed on diagnostic specimens obtained before treatment in all cases of AML and in 10 of 13 cases of MDS. As a comparator, we analyzed 18 cases of AML with core-binding factor (CBF) translocations, which have defined structural alterations, *inv(16)* with *CBFB::MYH11* or *t(8;21)* with *RUNX1::RUNX1T1* fusions, and lack *TP53* mutations or complex cytogenetics.

The demographics of the cohort, including age, sex, ethnicity, blood counts, blast percentages, and prior treatment are summarized in Table 1. Detailed characteristics are summarized in supplemental Table 2, and full clinical descriptions are provided for each case in supplemental Materials. The clinical characteristics of these groups were generally well matched, although patients with CBF AML were significantly younger ($P < .01$, *t* test) with higher white blood cell counts ($P < .01$, *t* test) and higher peripheral blast percentages ($P < .01$, *t* test) than in patients with *TP53*-mutated AML.

One patient had a clinical history of Li-Fraumeni syndrome, who presented with therapy-related MDS with excess blasts. An additional patient who presented with de novo AML had a germline frameshift variant in *CHEK2* (ENST00000328354.10:c.1100del), a pathogenic variant in Li-Fraumeni syndrome-2.²⁴ No other pathogenic germline variants in cancer-predisposing genes were identified in the cohort.

WGS improves the ability to identify mutations in the *TP53* gene

TP53 mutant allele status is an important prognostic factor. Biallelic *TP53* mutation, of all copies of the gene, with no remaining wild-type allele, is associated with decreased survival in MDS.^{4,5} Proving that 2 mutations affect separate alleles is difficult, therefore, in the absence of definitive proof, the term multihit is generally used for cases with either 2 distinct *TP53* mutations, a single mutation with chromosome 17p loss on karyotyping, or a single *TP53* mutation with high VAF on panel sequencing (with varying threshold requirements of 50%,^{1,3} 55%,⁵ or 60%⁶). Applying these conventional criteria to our cases (sequencing VAF > 55%, and cytogenetics), 93% of these AML cases and 69% of MDS cases were initially classified as multihit (Table 1); all events were confirmed by WGS. By adding WGS analysis, 5 additional cases (12%, 2 AML and 3 MDS) that initially appeared to be monoallelic (VAF < 50%) were found to have a second *TP53* mutation. With this increased sensitivity, 94% of cases in the cohort contained multihit *TP53* mutations, and the 1 remaining case (MDS with

Table 1. Clinical summary of myeloid malignancy cases

Cohort	TP53		CBF
	AML, n = 29	MDS, n = 13	AML, n = 18
Sex			
Male	66% (19)	31% (4)	56% (10)
Female	34% (10)	69% (9)	44% (8)
Age, y, mean (range)	65.7 (26-81)	61.3 (41-85)	45.5 (20-76)
Ethnicity			
Caucasian	97% (28)	100% (13)	100% (18)
African American	3% (1)		
WBC, mean (10 ³ cells per μ L)	9.3	5.0	34.0
BM blast %, mean	54%	7%	56%
PB blast %, mean	14%	2%	39%
Subtype			
M0	17% (5)		
M1	14% (4)		11% (2)
M2	17% (5)		33% (6)
M4	10% (3)		50% (9)
M5			6% (1)
M6	10% (3)		
M7	3% (1)		
MRC	14% (4)		
Not categorized	14% (4)		
Excess blasts		77% (10)	
Multilineage dysplasia		10% (3)	
Therapy related	3% (1)	38% (5)	
Secondary to MDS	10% (3)		
Cytogenetics			
Complex	90% (26)	100% (13)	
inv(3)	3% (1)		
del(Y)	3% (1)		
inv(16)			67% (12)
t(8;21)			28% (5)
Incomplete	3% (1)		6% (1)
Previous treatment			
None	100% (29)	77% (10)	100% (18)
Hypomethylating agent		15% (2)	
Lenolidomide		8% (1)	
TP53 status			
Concordant: multihit	93% (27)	69% (9)	
Discordant: monoallelic \rightarrow multihit	7% (2)	23% (3)	
Ambiguous \rightarrow monoallelic		8% (1)	

BM, bone marrow; MRC, myelodysplastic-related changes; PB, peripheral blood; WBC, white blood cell count.

TP53 VAF of 54% and complex cytogenetics) was found to be monoallelic. Furthermore, nearly all multihit events (92%) could be confidently verified as biallelic. Multihit mutations predominantly occurred as a single SNV/indel combined either with loss of the wild-type *TP53* allele (52%, n = 22), or CN-LOH (26%, n = 11; Figure 1A).

Examples of complex SV and CN-LOH that resulted in reclassification from monoallelic to multihit are illustrated. First, 1 patient (#480109) was previously classified as having MDS with monoallelic *TP53* mutation based on VAF of 32%; cytogenetics reported "add(17)(q11.2)" with no 17p abnormality detected. With WGS, a complex SV was identified involving multiple regions on




Figure 1. WGS results in the reclassification of some cases of *TP53*-mutated MDS/AML. (A) Combinations of mutation types affecting *TP53* in AML/MDS cases, and corresponding proportion in cohort. (B) Complex SV affecting the *TP53* genetic locus is detected using WGS based on resolution of rearrangements involving chr7, chr12, chr2, and *NF1* on chr17p. Copy-number losses are shown in red. Gray arcs indicate regions linked by SV. (C) CN-LOH affecting chr17p is detected using WGS based on shifts in B-allele frequency (top) whereas \log_2 copy-number ratio remains 0 (bottom). Vertical line indicates the position of the *TP53* locus.

chromosomes 2, 7, 12, and 17 including the *TP53* and *NF1* loci (Figure 1B). Reclassification to multihit *TP53* mutation increased the Molecular International Prognostic Scoring System (IPSS-M) risk stratification²⁵ from high to very high. Second, another patient (#147444) was previously classified as having MDS with monoallelic *TP53* mutation based on a VAF of 48.9% and lack of a 17p abnormality on cytogenetics. WGS identified CN-LOH on 17p (Figure 1C). Reclassification to multihit *TP53* mutation increased the IPSS-M stratification from moderately high to very high. In both

of these cases, the presence of multihit *TP53* mutations also affected the International Consensus Classification³ and the World Health Organization¹ diagnostic classifications.

***TP53*-mutated myeloid malignancies have a distinct pattern of somatic SNVs and indels**

The overall number of somatic point mutations and small indels was similar in *TP53*-mutated myeloid malignancies and CBF AML




Figure 2. Mutational landscape of *TP53*-mutated myeloid malignancies. *TP53*-mutated AML (left) and MDS (middle), compared with AML driven by the *CBFB::MYH11* or *RUNX1::RUNX1T1* fusion proteins. Top: SNV/indel counts for each sample. Left: frequency of selected genomic alterations in *TP53* samples. Middle: colors represent the types of mutations observed in each sample; asterisks indicate multiple SNV/indel hits. Bottom: proportion of each single-nucleotide base change per sample.

samples (Figure 2), and neither the mutation spectrum nor signatures suggested recurrent differences in mutational processes (supplemental Figure 1). The trend toward an increased number of mutations in *TP53*-mutated cases may reflect the older age of this cohort compared with the patients with CBF AML. An analysis of variant allele frequencies suggests the presence of subclonal populations in all 60 cases studied (supplemental Methods).

Cooperating mutations in *TP53*-mutated malignancies are distinct from other subtypes of AML. Mutations in common signaling genes *KIT* and *FLT3*, and also *WT1*,^{22,26} are absent (supplemental Table 3). Similarly, mutations in epigenetic modifiers (*DNMT3A*, *TET2*, or *ASXL1*) or spliceosome genes (*U2AF1*, *SF3B1*, *SRSF2*, or *ZRSR2*) are relatively uncommon, with a cumulative frequency of 14% and 4.8%, respectively. Furthermore, *NRAS* or *KRAS* mutations were present in only 7% (2 of 29) *TP53*-mutated AMLs vs 44% (8 of 18) CBF AMLs ($P = .009$). As an exception, the single case with a monoallelic *TP53* mutation (a patient with MDS with excess blasts) had cooperating SNVs not seen in other cases, including *ASXL1*, *U2AF1*, and *NRAS*, perhaps reflecting a distinct mechanism of transformation.

AML cases with *TP53* mutations were particularly enriched for comutations in *NF1*. SNVs, consisting mostly of frameshift or stop gains, were detected in 17.2% (5 of 29) of cases, and

copy-number loss was identified in 44.8% (13 of 29) of cases. All 5 cases with SNVs also had a loss of the second *NF1* allele, suggesting strong selection for multihit inactivation of *NF1* in *TP53*-mutated AML cases.

Specific chromosome alterations in *TP53*-mutated malignancies from different organs

Although aneuploidy is widespread in *TP53*-mutated myeloid malignancies, recurrent copy-number changes were evident and consistent with well-established cytogenetic changes, specifically loss of chr5, chr7, chr12, chr16, chr17, chr18, and chr20q, and gains in chr21, chr22, chr1p, and chr8 (Figure 2; supplemental Figure 2). A comparison to *TP53*-mutated solid tumors in the Pan-Cancer Analysis of Whole Genomes (PCAWG) data set²⁷ demonstrated striking differences in the patterns of recurrent copy-number changes (Figure 3). For example, loss of chr5q was present in >80% of the *TP53*-mutated myeloid malignancies in our study, compared with 58% and 38% of ovarian and esophageal adenocarcinomas, respectively, and <20% in any other tumor types. Similarly, chr7q loss was present in 56% of *TP53*-mutated myeloid tumors in our data set but was infrequent in all other *TP53*-mutated PCAWG tumor types. Conversely, some recurrent copy-number alterations that are common in other tumor types were only very rarely seen in *TP53*-mutated myeloid malignancies. For example, chromosome 6 loss was




Figure 3. Distinct patterns of copy-number alterations are observed in different *TP53*-mutated malignancies. The y-axis indicates the proportion of samples with a copy gain (blue, positive direction) or loss (red, negative direction) overlapping each gene, genome wide. Only mostly diploid samples without evidence of whole-genome doubling and with at least 50% of autosomes copy neutral are included. For the PCAWG data, all tumor types with at least 20 mostly diploid, *TP53*-mutated samples are included. Data sets included (top to bottom): *TP53*-mutated AML/MDS (n = 41), wild-type *TP53* CBF AML (n = 18), and *TP53*-mutated lymphoid (B-NHL, n = 20; CLL, n = 6), esophageal (n = 24), hepatic (n = 56), ovarian (n = 23), pancreatic (n = 96), and prostate (n = 43) malignancies. B-NHL, B-cell non-Hodgkin lymphoma; CLL, chronic lymphocytic leukemia.

observed in <2.5% of *TP53*-mutated myeloid tumors but is often detected in *TP53*-mutated solid tumors, including ovarian (83%), pancreatic (61%), and esophageal (29%) adenocarcinomas.

Of particular interest are *TP53*-mutated lymphoid malignancies (ie, non-Hodgkin lymphoma and chronic lymphocytic leukemia), which lack the recurrent copy-number losses observed in *TP53*-mutated myeloid malignancies. These groups share only a high frequency of loss of the p-arm of chromosome 17, which encompasses the *TP53* gene itself.

SV are frequent and often complex in *TP53*-mutated malignancies

In *TP53*-mutated AML/MDS samples, we observed a median of 71 somatic SVs per sample (range, 2-576 SVs; Figure 4A; supplemental

Table 4). This represents a significantly higher burden than observed in the CBF AML samples (median, 6; range, 3-14 SVs; $P = 5.6 \times 10^{-8}$, 2-sided Wilcoxon ranked-sums test). In the *TP53*-mutated samples, the majority of SV represented highly complex rearrangements (Figure 4B). Of 3948 SV in *TP53*-mutated samples, 2673 (68%) were part of a complex SV involving ≥ 20 individual SV calls. In the 42 *TP53*-mutated samples, we detected ≥ 1 complex events comprising >20 SVs in 26 samples (62%), and ≥ 1 complex events comprising >100 SVs in 8 samples (19%). Genome wide, an analysis of SV breakpoints occurring in 100-kilobase windows showed clear enrichment of breakpoints only at the inv(16) and t(8;21) loci for CBF AML samples (Figure 4C). In contrast, breakpoints were identified throughout the genome in *TP53*-mutated AML/MDS cases, with enrichment on 17p (containing *TP53*) and on 21 (with 1 hotspot occurring just upstream from *RUNX1*).




Figure 4. SV and chromothripsis involve very large, complex events in *TP53*-mutated myeloid malignancies. (A) Somatic SV call counts for each case. Counts colored per SV classification: breakends (BND), deletion (DEL), duplication (DUP), insertion (INS), and inversion (INV). (B) Distribution of somatic SV cluster sizes for each case. Counts colored per the number of individual SV events occurring within the corresponding complex SV cluster. (C) Frequency of somatic SV breakpoints in 100-Kb windows genome wide. Bar height indicates the fraction of samples with at least 1 SV breakpoint within each window. (top) Fraction of CBF AML with somatic SV breakpoints in each window. (bottom) Fraction of *TP53*-mutant AML with somatic SV in each window. In CBF AML, enrichment of breakpoints is clearly present at inv(16) and t(8;21) positions. Breakpoints are present throughout the genome in *TP53*-mutated AML/MDS cases, with enrichment on chr17 and chr21. (D) Large regions of chr5, chr12, chr16, and chr17 are involved in complex rearrangements affecting copy number, including the *TP53* genomic locus in a case of *TP53*-mutated AML (UPN 983349). (Outer track) copy gains (blue) and losses (red). (Inner track) regions involved in high-confidence chromothripsis events (dark blue). Gray arcs indicate novel adjacencies created by structural rearrangements. (E) Chromothripsis is detectable in 60% of *TP53*-mutated myeloid malignancies and is not present in any CBF AML cases. (F) Genome-wide distribution of high-confidence chromothripsis calls. Proportion of all *TP53*-mutated PCAWG (top; n = 623) and AML/MDS (bottom; n = 42) samples with a chromothripsis call on each chromosome.

Chromothripsis is common in myeloid malignancies with a complex karyotype, with a reported frequency of 35% based on single-nucleotide polymorphism arrays.²⁸ Chromothripsis arises from the attempted repair of extensive double-strand break fragmentation across regions of ≥ 1 chromosomes. The definition of

chromothripsis includes the following: (1) clustering of breakpoints with large regions of interleaving normal sequence; (2) oscillations between 2 or 3 copy-number states; and (3) rearrangements of multiple fragments in random orientation and order.²⁹ Using ShatterSeek to define high-confidence regions of

chromothripsis,¹⁹ 60% (25 of 42) of *TP53*-mutated myeloid malignancies exhibited chromothripsis (Figure 4D; supplemental Table 5). In contrast, chromothripsis was not observed in any CBF AML samples. Of the 25 *TP53*-mutated AML/MDS samples with at least 1 high-confidence chromothripsis region, nearly half (48%; 12 of 25) had high-confidence regions detected on >1 chromosome (refer to Figure 4E for an example). In *TP53*-mutated AML/MDS, chromothripsis events occurred most frequently on chr5 (7 of 43 chromothripsis events), chr17 (5 of 43 chromothripsis events), and chr21 (4 of 43 chromothripsis events). This pattern is distinct from that observed across 603 *TP53*-mutated samples from the PCAWG consortium,¹⁹ in which 408 high-confidence chromothripsis regions were reported in 246 samples (38.2% of 19 different tumor types, but only 1 sample with myeloid malignancy; Figure 4F). We note that the 7 samples with chromothripsis within chr5 were a subset of the 33 samples with 5q loss, and do not represent biallelic loss of 5q. Three genomic regions were recurrently affected by chromothripsis in ≥ 4 of the *TP53*-mutated AML/MDS samples: an 87-Mb region of chr5q, in which the chromothripsis events involved large copy losses on 5q; a 6.2-Mb region on chr17q containing *NF1*, in which all 3 of 4 samples with chromothripsis exhibited a focal (<3 Mb) copy loss of *NF1* and the fourth contained a disruptive SV breakpoint within the *NF1* gene body; and a 12.8-Mb region on chr21q containing *RUNX1*, in which 3 of 4 samples with chromothripsis contained a disruptive SV breakpoint within the *RUNX1* gene body.

Reduced expression of *ETV6* is frequent in *TP53*-mutated myeloid malignancies

Copy-number losses on the p-arm of chromosome 12 occur frequently in *TP53*-mutated AML/MDS, affecting 45% (19 of 42) of samples in this cohort (supplemental Tables 6 and 7). The minimally deleted region of 12p spans 2.75 Mb, and includes the gene bodies of 18 protein-coding genes, including the tumor suppressors *ETV6* and *CDKN1B* (Figure 5A). Both *ETV6* and *CDKN1B* were also frequently deleted in *TP53*-mutated samples in the Beat AML cohort,²⁶ with coordinate loss of each in 32% (6 of 19) of cases, compared with 1.7% (4 of 238) of non-*TP53*-mutated primary AML samples (odds ratio, 26; 95% confidence interval, 5.4-141.9; $P = 1.3 \times 10^{-5}$, 2-sided Fisher exact test, supplemental Table 8). We detected no somatic SNVs, indels, or fusions in either gene, nor in *TP53*-mutant cases from the Beat AML cohort.

RNA-sequencing data of genes in the minimally deleted region (Figure 5B) revealed that *ETV6* was highly expressed in CBF and normal karyotype (NK) AMLs, and had significantly lower expression in *TP53*-mutated AMLs with 12p loss (adjusted P value = 1×10^{-4} ; Figure 5C; supplemental Table 9). In contrast, expression of *CDKN1B* in cases with a 12p deletion was similar to that observed in CBF or NK AMLs. Of note, a trend toward increased *CDKN1B* expression in 12p-intact *TP53*-mutant samples was observed, suggesting that its downregulation may not be an essential feature of *TP53*-mutant AML. The other gene with significantly decreased expression concordant with 12p deletion was *DDX47* (adjusted P value = 4×10^{-8}); however, this gene is not highly expressed in CBF and NK AMLs, and has no documented function in hematopoietic cells.

Surprisingly, decreased *ETV6* expression was also observed in *TP53*-mutated myeloid malignancies without 12p structural

rearrangements (adjusted P value = .021; Figure 5C). This observation was confirmed in an extension cohort of messenger RNA (mRNA) data from The Cancer Genome Atlas Program²² (P values < .02 and .002 compared with CBF and NK AML cases, respectively; Figure 5D). No regulatory mutations in the *ETV6* promoter or nearby enhancers were detected, nor was *ETV6* promoter methylation altered in a cohort of 29 previously published samples with whole-genome bisulfite sequencing.²³ Further studies will be needed to understand the genetic or epigenetic mechanisms governing *ETV6* dysregulation in *TP53*-mutant myeloid malignancies.

Telomere content is increased in *TP53*-mutated myeloid malignancies

Excessive replication of leukemic blasts is expected to decrease telomere length in myeloid malignancies.³⁰⁻³³ Indeed, reduced telomere content was detected in leukemic CBF AML bone marrow cells, compared with matched normal tissue obtained at the same time (mean shortening 226 telomeric reads per GC content-matched million reads; $P = 8.3 \times 10^{-7}$; Figure 6A; supplemental Table 10). Surprisingly, telomere content in *TP53*-mutated myeloid tumors was similar between leukemic and matched normal tissues. By normalizing tumor telomeric content to the paired normal for each sample (to account for age-related telomere shortening; supplemental Figure 3), we observed significantly less telomere shortening in *TP53*-mutant AML/MDS cases, compared with CBF AMLs ($P = 1.7 \times 10^{-5}$; Figure 6B).

There are 2 candidate mechanisms by which telomere extension might occur. The first is a telomerase-dependent pathway, which has been associated with TTTGGG telomeric repeats.²¹ An analysis of telomere variant repeats in singleton context (ie, variant hexamers flanked by at least 3 t-type hexamers to each side) showed that telomeric repeats containing TTTGGG hexamers were significantly increased in *TP53*-mutated AML/MDS compared with the CBF subset ($P = 1.4 \times 10^{-7}$; Figure 6C). Telomerase-dependent telomere extension in solid tumors is frequently associated with extensive SV and copy-number amplifications affecting *TERT* expression.³⁴ We observed copy-number events affecting the *TERT* locus on chr5p resulting in amplification in 2 samples, and a single *TERT* copy loss in 2 samples (supplemental Table 6). We did not observe any somatic SNVs, indels, or SVs affecting either the *TERT* gene body or promoter region. No significant difference in *TERT* mRNA expression was observed in *TP53*-mutated AML/MDS samples (supplemental Figure 4).

The second canonical mechanism of telomere extension is through the alternative lengthening of telomeres pathway, which has previously been associated with interstitial insertions of telomere sequences. Abnormal insertions of telomeric repeats adjacent to intrachromosomal regions (example shown in Figure 6D; supplemental Table 11) were detected in 13 (31%) *TP53*-mutated AML/MDS tumor samples but in none of the CBF tumor samples ($P = .0061$, Fisher exact test; Figure 6E). Of these 13 samples, 9 contained a single telomeric insertion; the remaining 4 contained ≥ 2 insertion sites. Within the subset of *TP53*-mutated samples, these telomeric insertions were associated with higher overall SV counts ($P = .0033$, Wilcoxon ranked-sums test, Figure 6F) and showed a trend toward the presence of chromothripsis that was not statistically significant (Figure 6G). The telomeric insertions




Figure 5.

tended to occur in close proximity to structural variations: 26% (5 of 19) occurred within 10 kb of a high-confidence chromothripsis region, and 68% (13 of 19) occurred within 10 kb of an SV breakpoint. *ATRX* or *DAXX* have been implicated in the alternative lengthening of telomeres pathway; notably, we did not observe any somatic SNVs, indels, or SVs affecting these genes. Similarly, *ATRX* and *DAXX* RNA expression did not significantly differ between the *TP53*-mutant and CBF or NK AMLs (supplemental Figure 4).

Discussion

The complex genomes of *TP53*-mutated myeloid malignancies make genomic characterization of these cases difficult with traditional methods, including karyotyping, FISH, DNA microarrays, or targeted sequencing panels. To our knowledge, this study represents the largest WGS characterization of *TP53*-mutated myeloid malignancies reported to date, and resolves the frequency, size, and complexity of acquired SV in these very disordered genomes. Novel observations using this approach include: (1) accurate determination of *TP53* allele status by WGS reclassifies cases from monoallelic to multihit, which improves accuracy of IPSS-M risk prognosis for MDS; (2) aneuploidy in *TP53*-mutated AML/MDS differs remarkably from other cancers; (3) *ETV6* is deleted in 45% of cases, with evidence for suppression in nondeleted cases; and (4) telomere content is higher in AML/MDS with *TP53* mutations.

Multihit *TP53* mutations are indicative of dismal prognosis in myeloid malignancies^{4,5} and are included in the International Consensus Classification³ and the World Health Organization¹ classifications for MDS. We observed more frequent multihit involvement of *TP53* (94%, with 92% of those unambiguously biallelic) compared with previous studies (76% of AML or MDS with excess blasts⁵; 63% of MDS⁴). This is likely because of a combination of cohort composition, with a higher number of complex karyotype cases,⁵ and better ascertainment provided by WGS. Current practices relying on cytogenetics and VAF thresholds for *TP53* mutations miss multihit events in 12% of this cohort, and up to 25% of previously reported MDS cohorts,^{4,35} and may also underperform in peripheral blood samples or hemodilute bone marrow aspirates.

Chromosomal patterns of both aneuploidy and chromothripsis differed remarkably in *TP53*-mutated myeloid cancers vs lymphoid malignancies or solid tumors. Myeloid malignancies are known to involve losses of large regions on chromosomes 5 and 7⁴ or chromothripsis,²⁸ which we resolve to base-pair level breakpoints in many cases. Aneuploidy in *TP53*-mutated solid/lymphoid malignancies affects a substantially different pattern of chromosomes, but this has been previously unreported because of a paucity of myeloid malignancies in the PCAWG data set (1 case with *TP53*-mutated AML). Chromosomal alterations induced by *TP53*

mutations are specific to cell lineage, which previous models have suggested may arise because of sensitivity to disruptions, in particular transcription factors and signaling networks,^{36,37} or because of chromosome architecture and transcriptional activity.³⁸

Although activating mutations in signaling proteins, such as *NRAS* and *KRAS*, are frequently observed in AML, they are relatively uncommon in *TP53*-mutated AML. In this cohort, we detected a strong enrichment of mutations in *NF1*, a negative regulator of Ras signaling. Previous studies identified *NF1* mutations at frequencies of ~5% for SNVs³⁹ and 7% for SVs⁴⁰ in all AMLs, and enrichment in complex karyotype AML of 9% for SNVs⁴¹ and 30% for SVs (with resolution to 0.1-2 Mb),⁴² although low *NF1* RNA expression³⁹ or high VAF⁴¹ suggested that these might be underestimated. Our observation of 45% of AML cases with *NF1* mutations, with 17% of those being multihit, exceeds those estimates substantially and suggests strong cooperativity with *TP53*. The increased resolution of WGS identified 6 *NF1* copy-number losses <3 Mb in size, not easily detectable with karyotyping. Additional studies will be needed to determine the mechanisms describing why *NF1* mutations are preferentially selected for in a *TP53*-mutant context.

In this study, 45% of *TP53*-mutated AML/MDS samples had deletion of the p-arm of chromosome 12 with a minimally deleted region that included *ETV6*, consistent with other studies of complex karyotype AML,⁴³ and far higher than non-complex karyotype AML or MDS (0.2%-3%).⁴⁴ Gene expression data helped us nominate *ETV6* as the most likely target gene in this region, although we cannot completely discount synergistic effects with other genes in the region, such as *CDKN1B*. This also led to the curious finding that *ETV6* mRNA expression is decreased in *TP53*-mutated AML/MDS samples, even in those without 12p deletions, this suggests that downregulation of *ETV6* gene expression, mediated either by genetic or epigenetic mechanisms, may be important for the pathogenesis of *TP53*-mutated myeloid malignancies.

Our findings in CBF AMLs confirm previous studies in AML and MDS demonstrating shortened telomeres,³⁰⁻³³ which play an essential role in genomic stability and shorten with each cell division.⁴⁵ In contrast, we observed no significant decrease in the telomere content of *TP53*-mutated myeloid malignancies, as was similarly reported in a recent conference abstract.⁴⁶ We found support for both telomerase-dependent telomere extension, with an increase in TTTGGG telomeric repeats, and for ALT pathway telomere extension, with interstitial telomeric content. Furthermore, we may be underestimating interstitial telomeric content, because short-read WGS is not well suited to assess highly-repetitive telomere sequence.²¹ In solid tumors, these pathways are most often activated by high *TERT* expression or by *ATRX* or *DAXX*

Figure 5. *ETV6* deletion and decreased expression is common in *TP53*-mutated myeloid malignancies. (A) Genomic locations of copy-number losses intersecting the minimally deleted region on chr12p (n = 19). Locations of all protein encoding genes intersecting this region are shown. (B) mRNA expression for genes within the minimally deleted region of chr12p, displayed for genes with a minimum mean expression of 10 counts per million mapped reads for at least 1 group. Boxplot indicates median and first and third quartiles; whiskers indicate the range of all data points falling within 1.5 × interquartile range (IQR). CBF AML (n = 11); NK AML (n = 52); *TP53*-mutated with 12p intact (n = 6); and *TP53*-mutated with 12p loss (n = 8). (C) mRNA expression of *ETV6* in *TP53*-mutated samples with and without 12p loss, compared with NK and CBF AML cases (n = 8, 6, 52, and 11, respectively). *Adjusted P value < .05, edgeR exactTestDoubleTail with adjustment for multiple comparisons. (D) Extension cohort of additional cases from the previously published The Cancer Genome Atlas Program AML data set. mRNA expression of *ETV6* in *TP53*-mutated samples with 12p loss and with 12p intact (n = 4 and 11, respectively), NK (n = 79), CBF (n = 18), and 12p loss (*TP53* wild type, n = 4) samples. *Adjusted P value < .05, t test with multiple testing correction.




Figure 6. Telomere content is increased in *TP53*-mutated myeloid malignancies. (A) Telomere content in units of telomeric reads per GC content–matched million reads (TRPM) was quantified in WGS from tumor specimens (orange) and paired germ line control tissues (skin or buccal DNA, blue) for CBF AML and *TP53*-mutated myeloid malignancies. Significant telomere shortening in the CBF sample subset, with a mean shortening of 226 telomeric reads per GC content–matched million reads (TRPM; $P = 8.3 \times 10^{-7}$; 2-sided, paired t test) but not in the *TP53*-mutant subset (mean difference of -2.5 TRPM between tumor and normal). (B) Ratio of telomere content for tumor compared with normal tissue. *TP53*-mutated myeloid malignancies have significantly higher telomere content compared with CBF AML ($P = 1.7 \times 10^{-5}$, 2-sided t test). (C) Relative abundance of telomere variant repeats (TVR) in singleton context. Log₂ tumor-to-normal ratio of singleton TVR repeats in *TP53*-mutant and CBF subtypes. The relative abundance of singleton TTTGGG repeats is significantly higher in *TP53*-mutated myeloid malignancies compared with CBF AML ($P = 1.4 \times 10^{-7}$, 2-sided t test). (D) Example of intrachromosomal insertion of t-type telomeric hexamer sequences seen in the tumor but not the paired normal sequence data from a *TP53*-mutated case (UPN 387082). (E) Fractions of patients with *TP53*-mutated myeloid malignancies ($n = 42$) and CBF AML ($n = 18$) with detectable interstitial (nontelomere) telomeric repeat variants ($P = .006$, Fisher exact test). (F) *TP53*-mutated cases with detectable interstitial insertions of telomeric variant repeats have higher SV counts ($P = .0033$, Wilcoxon ranked-sums test). (G) Fraction of *TP53*-mutated cases with detectable interstitial insertions of telomeric variant repeats in sample with ($n = 25$) and without ($n = 17$) chromothripsis (P value, not significant; odds ratio, 3.03; 95% confidence interval, 0.61-20.7; Fisher exact test).

truncating mutations. However, for these cases, we observed only 2 with of *TERT* copy-number gains, which does not sufficiently explain this observation across the entire cohort. We conclude that *TP53*-mutated myeloid malignancies may use unique, as yet undefined mechanisms to induce telomere maintenance.

In summary, WGS of AML/MDS with paired normal tissue provides the most complete characterization to date of the genomic landscape of *TP53*-mutated myeloid malignancies. These data emphasize the unique features of these cancers, including the high frequency of chromothripsis and SV, and the involvement of unique

signaling genes, including *NF1* and *ETV6*. Finally, we provide evidence that telomere maintenance is altered in *TP53*-mutated myeloid malignancies. These pathways may represent potential new targets for therapeutic intervention.

Acknowledgments

Research support includes the Genomics of Acute Myeloid Leukemia Program Project grant, National Cancer Institute (NCI) P01 CA101937 (D.C.L. and T.J.L.), Specialized Program of Research Excellence in Leukemia NCI P50 CA171963 (D.C.L.), NCI K12 CA167540 (K.A.O. and R.B.D.), NCI R50 CA211782 (C.A.M.), and an American Society of Hematology award (K.A.O.). Core services were provided by the Alvin J. Siteman Cancer Center Tissue Procurement Core and Biostatistics Shared Resource Core through NCI Cancer Center grant P30CA091842, the Cytogenomics and Molecular Pathology Laboratory, Genome Technology Access Center, and the McDonnell Genome Institute at the Washington University School of Medicine.

Authorship

Contribution: H.J.A., K.A.O., C.A.M., D.C.L., T.J.L., M.J.W., and J.F.D. designed the study; S.E.H., P.W., R.B.D., S.P.T., and J.E.P. performed tissue repository sample identification and clinical annotations; R.S.F., C.C.F., N.M.H., D.H.S., E.J.D., and M.C.S. performed data acquisition; H.J.A., C.A.M., K.A.O., S.M.R.,

S.N.S., D.H.S., E.J.D., and M.C.S. performed data analysis; H.J.A., K.A.O., C.A.M., D.C.L., and T.J.L. wrote the manuscript draft; and all authors reviewed and contributed to the final manuscript.

Conflict-of-interest disclosure: J.F.D. has an equity ownership position in Magenta Therapeutics and WUGEN, and receives research funding from Amphivena Therapeutics, Neolmmune Tech, MacroGenics, Incyte, BiolineRx, and WUGEN. D.H.S. has received research funding from Illumina and consultant fees and stock options from WUGEN. E.J.D. is a consultant for Cofactor Genomics, Genescopy LLC, and Vertex, and has received honoraria from Blueprint Bio, AbbVie, and Illumina. Funding from these sources was not used for this study. The remaining authors declare no competing financial interests.

ORCID profiles: K.A.O., [0000-0002-2846-8831](https://orcid.org/0000-0002-2846-8831); C.A.M., [0000-0003-4266-6700](https://orcid.org/0000-0003-4266-6700); S.M.R., [0000-0002-4500-6583](https://orcid.org/0000-0002-4500-6583); R.B.D., [0000-0002-4376-4663](https://orcid.org/0000-0002-4376-4663); C.C.F., [0000-0002-2766-9551](https://orcid.org/0000-0002-2766-9551); S.P.T., [0000-0002-7970-702X](https://orcid.org/0000-0002-7970-702X); M.C.S., [0000-0003-4389-043X](https://orcid.org/0000-0003-4389-043X); J.E.P., [0001-8832-3661](https://orcid.org/0001-8832-3661); D.H.S., [0000-0002-5314-3043](https://orcid.org/0000-0002-5314-3043); D.C.L., [0000-0002-3170-7581](https://orcid.org/0000-0002-3170-7581).

Correspondence: Daniel C. Link, Division of Oncology, Department of Medicine, Washington University School of Medicine, 660 South Euclid Ave, Campus Box 8007, St. Louis, MO 63110; email: danielclink@wustl.edu.

References

1. Khoury J, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. *Leukemia*. 2022;36(7):1703-1719.
2. Rücker FG, Schlenk RF, Bullinger L, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. *Blood*. 2012;119(9):2114-2121.
3. Arber DA, Orazi A, Hasserjian RP, et al. International Consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. *Blood*. 2022;140(11):1200-1228.
4. Bernard E, Nannya Y, Hasserjian RP, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. *Nat Med*. 2020;26(10):1549-1556.
5. Grob T, Al Hinai ASA, Sanders MA, et al. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. *Blood*. 2022;139(15):2347-2354.
6. Weinberg OK, Siddon A, Madanat YF, et al. TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML. *Blood Adv*. 2022;6(9):2847-2853.
7. Duncavage EJ, Schroeder MC, O'Laughlin M, et al. Genome sequencing as an alternative to cytogenetic analysis in myeloid cancers. *N Engl J Med*. 2021;384(10):924-935.
8. Takahashi K, Wang F, Kantarjian H, et al. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. *Lancet Oncol*. 2017;18(1):100-111.
9. Gillis NK, Ball M, Zhang Q, et al. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. *Lancet Oncol*. 2017;18(1):112-121.
10. Wong TN, Ramsingh G, Young AL, et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. *Nature*. 2015;518(7540):552-555.
11. Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. *arXiv*. Preprint posted online 16 March 2013. <https://doi.org/10.48550/arXiv.1303.3997>
12. Cibulskis K, Lawrence MS, Carter SL, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. *Nat Biotechnol*. 2013;31(3):213-219.
13. Koboldt DC, Zhang Q, Larson DE, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. *Genome Res*. 2012;22(3):568-576.
14. Kim S, Scheffler K, Halpern AL, et al. Strelka2: fast and accurate calling of germline and somatic variants. *Nat Methods*. 2018;15(8):591-594.

15. Van der Auwera GA, O'Connor BD. *Genomics in the Cloud: Using Docker, GATK, and WDL in Terra*. "O'Reilly Media, Inc."; 2020.
16. Cameron DL, Baber J, Shale C, et al. GRIDSS2: comprehensive characterisation of somatic structural variation using single breakend variants and structural variant phasing. *Genome Biol.* 2021;22(1):202.
17. Priestley P, Baber J, Lolkema MP, et al. Pan-cancer whole-genome analyses of metastatic solid tumours. *Nature.* 2019;575(7781):210-216.
18. Shale C, Cameron DL, Baber J, et al. Unscrambling cancer genomes via integrated analysis of structural variation and copy number. *Cell Genom.* 2022; 2(4):100112.
19. Cortés-Ciriano I, Lee JJ-K, Xi R, et al. Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. *Nat Genet.* 2020;52(3):331-341.
20. Feuerbach L, Sieverling L, Deeg KI, et al. TelomereHunter - in silico estimation of telomere content and composition from cancer genomes. *BMC Bioinformatics.* 2019;20(1):272.
21. Sieverling L, Hong C, Koser SD, et al. Genomic footprints of activated telomere maintenance mechanisms in cancer. *Nat Commun.* 2020;11(1):733.
22. Cancer Genome Atlas Research Network, Ley TJ, Miller C, Ding L, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. *N Engl J Med.* 2013;368(22):2059-2074.
23. Upadhyay P, Beales J, Shah NM, et al. Recurrent transcriptional responses in AML and MDS patients treated with decitabine. *Exp Hematol.* 2022;111:50-65.
24. Bell DW, Varley JM, Szydlo TE, et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. *Science.* 1999;286(5449):2528-2531.
25. Bernard E, Tuechler H, Greenberg Peter L, et al. Molecular International Prognostic Scoring System for myelodysplastic syndromes. *NEJM Evidence.* 2022;1(7):EVIDoA2200008.
26. Tyner JW, Tognon CE, Bottomly D, et al. Functional genomic landscape of acute myeloid leukaemia. *Nature.* 2018;562(7728):526-531.
27. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. *Nature.* 2020;578(7793):82-93.
28. Rucker FG, Dolnik A, Blätte TJ, et al. Chromothripsis is linked to TP53 alteration, cell cycle impairment, and dismal outcome in acute myeloid leukemia with complex karyotype. *Haematologica.* 2018;103(1):e17-e20.
29. Korb J, Campbell PJ. Criteria for inference of chromothripsis in cancer genomes. *Cell.* 2013;152(6):1226-1236.
30. Williams J, Heppel NH, Britt-Compton B, et al. Telomere length is an independent prognostic marker in MDS but not in de novo AML. *Br J Haematol.* 2017;178(2):240-249.
31. Park HS, Choi J, See CJ, et al. Dysregulation of telomere lengths and telomerase activity in myelodysplastic syndrome. *Ann Lab Med.* 2017;37(3):195-203.
32. Watts JM, Dumitriu B, Hilden P, et al. Telomere length and associations with somatic mutations and clinical outcomes in acute myeloid leukemia. *Leuk Res.* 2016;49:62-65.
33. Gerbing RB, Alonzo TA, Sung L, et al. Shorter remission telomere length predicts delayed neutrophil recovery after acute myeloid leukemia therapy: a report from the Children's Oncology Group. *J Clin Oncol.* 2016;34(31):3766-3772.
34. Zhang Y, Chen F, Fonseca NA, et al. High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterations. *Nat Commun.* 2020;11(1):736.
35. Yoshizato T, Nannya Y, Atsuta Y, et al. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. *Blood.* 2017;129(17):2347-2358.
36. Short NJ, Montalban-Bravo G, Hwang H, et al. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. *Blood Adv.* 2020;4(22):5681-5689.
37. Sack LM, Davoli T, Li MZ, et al. Profound tissue specificity in proliferation control underlies cancer drivers and aneuploidy patterns. *Cell.* 2018;173(2): 499-514.e23.
38. Canela A, Maman Y, Jung S, et al. Genome organization drives chromosome fragility. *Cell.* 2017;170(3):507-521.e18.
39. Eisfeld A-K, Kohlschmidt J, Mrózek K, et al. NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. *Leukemia.* 2018; 32(12):2536-2545.
40. Parkin B, Ouillette P, Wang Y, et al. NF1 inactivation in adult acute myelogenous leukemia. *Clin Cancer Res.* 2010;16(16):4135-4147.
41. Moison C, Lavallée V-P, Thiollier C, et al. Complex karyotype AML displays G2/M signature and hypersensitivity to PLK1 inhibition. *Blood Adv.* 2019; 3(4):552-563.
42. Rucker FG, Bullinger L, Schwaenen C, et al. Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. *J Clin Oncol.* 2006;24(24):3887-3894.
43. Feurstein S, Rucker FG, Bullinger L, et al. Haploinsufficiency of ETV6 and CDKN1B in patients with acute myeloid leukemia and complex karyotype. *BMC Genomics.* 2014;15(1):784.
44. Wang Q, Dong S, Yao H, et al. ETV6 mutation in a cohort of 970 patients with hematologic malignancies. *Haematologica.* 2014;99(10):e176-e178.
45. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. *Nature.* 1990;345(6274):458-460.
46. Wahida A, Hutter S, Gurnari C, et al. Mutant TP53 prevents telomere shortening in acute myeloid leukemia. *Blood.* 2021;138(suppl 1):375.